Israeli health tech startup Quris AI, which uses artificial intelligence (AI) to develop drugs, has added another $19 million to its seed funding round, bringing in a total of $28 million in seed funding, the company announced Tuesday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
The round was led by WellTech Ventures, and included iAngels and GlenRock Capital, as well as additional private investors.
Quris AI plans to use to money for research and development, increase its personnel, and expand collaborations with other companies.
Since launching its platform at the end of last year, Quris AI has completed development of the first drug based on its platform, which is designed to treat Fragile X Syndrome, a genetic disorder that causes developmental delays.
Quris AI was founded in 2020 by serial med-tech and AI entrepreneurs Dr. Isaac Bentwich, CEO, and Yossi Haran, CTO. The company employs 20 people and hopes to double its workforce by the end of 2022.
